52 results
Page 2 of 3
8-K
EX-2.1
cenrfhvg9 goxeu
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-10.1
fasrcw9n
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
424B3
rs5u 3j0e9ygeszk0dk9
30 Apr 21
Prospectus supplement
5:01pm
8-K
EX-10.2
23q4a
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-2.1
grhbxrydyr3
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-10.1
gg8s21c gk
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
424B5
f8wsr tetb89tig
31 Dec 19
Prospectus supplement for primary offering
4:28pm
8-K
EX-4.1
q5zryiy
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
kkynxubp8rxa1216s oc
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B3
p22ohd5zao
18 Nov 19
Prospectus supplement
4:53pm
8-K
EX-10.2
pruvwp ax9lpnku16ov
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
EX-10.1
xhqglvmey2pps
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am